Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma

First-of-its-kind commercial partnership between pharmaceutical and digital health companies in respiratory medicine

Madison, Wisconsin and Ridgefield, Connecticut – March 23, 2016 – Propeller Health, the leading digital health solution for respiratory medicine, and Boehringer Ingelheim Pharmaceuticals Inc., a global pharmaceutical company and leading provider of inhaled medications for serious respiratory diseases, today announced a first-of-its-kind commercial partnership that aims to use digital health tools and services to help people living with chronic obstructive pulmonary disease (COPD) and asthma better manage their disease.

Under the terms of the partnership, people living with COPD and asthma, who are being treated with a Boehringer Ingelheim prescription medication approved for use in the company’s RESPIMAT® inhaler, will have the opportunity to enroll at select U.S. health systems in a new program that is designed to determine how Propeller’s novel health technology tool for the RESPIMAT inhaler impacts adherence rates and patient engagement.

In March 2015, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to market Propeller’s health technology platform in association with the RESPIMAT inhaler.  Propeller uses a combination of inhaler sensors, apps, analytics, personal feedback and education. The platform passively tracks how and when each patient uses their inhaled medications and can send alerts to patients and their caregivers. Propeller creates a custom view for each patient, allowing them to better understand the impact and management of their disease in daily life.

The RESPIMAT is the platform inhaler for the Boehringer Ingelheim respiratory medications. For more information about the RESPIMAT inhaler and the medicines approved for use in the RESPIMAT, please visit www.us.respimat.com.

“We are excited to work with Boehringer Ingelheim to bring Propeller to people with asthma and COPD at health systems across the U.S. Together, we believe that digital tools can complement the use of  respiratory medications and encourage more appropriate and effective management of chronic respiratory disease,” said David Van Sickle, CEO of Propeller.

“As a committed partner to the respiratory community for nearly a century, Boehringer Ingelheim is proud to embark on this industry-leading partnership with Propeller with the goal of improving the care of people living with COPD and asthma,” said Ruchin Kansal, executive director and head, Business Innovation, Boehringer Ingelheim Pharmaceuticals, Inc.

Propeller has been used by people with respiratory diseases in over 40 commercial programs across the U.S., including major healthcare systems, payers, employers and other organizations. It is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers (MDIs), and other inhaler devices (dry powder inhaler (DPI) and soft mist inhaler (SMI)).

About Propeller Health
Founded in 2010, Propeller is the leading provider of an FDA-cleared digital health platform that helps reduce the cost of care while delivering better quality of life for individuals with chronic respiratory disease. Propeller provides better engagement, communication, and more insightful and personalized care. Backed by Safeguard Scientifics (NYSE: SFE), Social Capital, California HealthCare Foundation, Kapor Capital and other investors, Propeller has been used by patients with asthma or COPD in over 40 commercial programs across the US at major healthcare systems, payers, employers and other commercial partners. Company recognition includes TEDMED Innovation Showcase, White House Champion of Change, and Bluetooth Breakthrough Product awards.

Contact us at [email protected] to discuss how Propeller can empower patients and create value in your organization.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2014, Boehringer Ingelheim achieved net sales of about $16.96 billion dollars (13.3 billion euros). R&D expenditure corresponds to 19.9 percent of its net sales.

For more information please visit http://us.boehringer-ingelheim.com/, or follow us on Twitter @BoehringerUS.

Contacts:

Propeller Health
[email protected]
1-608-251-0470
www.propellerhealth.com
@PropellerHealth

Boehringer Ingelheim
[email protected]
1-203-798-4375
http://us.boehringer-ingelheim.com
@boehringerUS